Latest News and Press Releases
Want to stay updated on the latest news?
-
FibroGen Exclusively Licenses HiFiBiO’s Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 ProgramsTransformative Transaction for FibroGen’s Early-stage Pipeline HiFiBiO to...
-
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
-
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...
-
Roxadustat net product revenue in China of $15.4 million, on a US GAAP basis Total roxadustat net sales in China of $43.5 million1 by FibroGen and the distribution entity jointly owned by FibroGen and...
-
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close. FibroGen will also...
-
SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities...
-
SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for...
-
SAN FRANCISCO, April 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the company’s...
-
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively...
-
Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat Company to Host Investor Call Today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) SAN FRANCISCO, April 06, 2021 ...